

# LSP-249

Cat. No.: HY-126378 CAS No.: 1801253-04-2 Molecular Formula:  $C_{24}H_{22}CIN_{5}O$ 

Molecular Weight: 431.92

Target: Ser/Thr Protease

Pathway: Metabolic Enzyme/Protease Storage: Powder -20°C 3 years

4°C 2 years

-80°C In solvent 6 months

> -20°C 1 month

**Product** Data Sheet

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 31.25 mg/mL (72.35 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.3152 mL	11.5762 mL	23.1524 mL
	5 mM	0.4630 mL	2.3152 mL	4.6305 mL
	10 mM	0.2315 mL	1.1576 mL	2.3152 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.82 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.08 mg/mL (4.82 mM); Suspended solution; Need ultrasonic
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.82 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

Description LSP-249 (example 35), extracted from patent WO2016011209A1, is a plasma kallikrein inhibitor under the study for angioedema, with an  $EC_{50}$  less than 100 nM in  $cell^{[1]}$ .

EC50⊠< 100 nM (kallikrein in cell)<sup>[1]</sup>. IC<sub>50</sub> & Target

#### **REFERENCES**

1]. Andrew Mcdonald, et al. Therapeutic inhibitory compounds. Patent. WO2016011209A1.							
	Caution: Product has not	been fully validated for med	lical applications. For research use c	only.			
	Tel: 609-228-6898	Fax: 609-228-5909	E-mail: tech@MedChemExpress.				
	Address: 1 De	eer Park Dr, Suite Q, Monmoi	uth Junction, NJ 08852, USA				

Page 2 of 2 www.MedChemExpress.com